




The relative strengths and weaknesses of Lantern Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lantern Pharma Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 190% points. The greatest weakness of Lantern Pharma Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 380%, being 166% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	43,341
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,678
Liabilities, Non-Current	61
Other Assets	254
Other Compr. Net Income	264
Other Expenses	0
Other Liabilities	0
Other Net Income	1,916
Other Revenues	0
Property and Equipment	52
Research and Development	11,894
Selling, General and Administrative Expense	5,983

Output Variable	Value in 1000 USD
Assets	43,648
Liabilities	2,740
Expenses	17,878
Revenues	0
Stockholders Equity	40,908
Net Income	-15,962
Comprehensive Net Income	-15,830
BaseVar	33,222
ECR before LimitedLiability	316%
Economic Capital Ratio	380%